{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:54:05Z","timestamp":1776682445953,"version":"3.51.2"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","seizure-journal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.seizure.2024.02.006","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T16:51:45Z","timestamp":1707843105000},"page":"105-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Clinical observation and analysis of rash caused by lacosamide in children with epilepsy"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9954-984X","authenticated-orcid":false,"given":"Yingying","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Pt A","key":"10.1016\/j.seizure.2024.02.006_bib0001","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.yebeh.2015.09.006","article-title":"Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials","volume":"52","author":"Biton","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.seizure.2024.02.006_bib0002","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1684\/epd.2014.0667","article-title":"Lacosamide-induced rash","volume":"16","author":"Koubeissi","year":"2014","journal-title":"Epileptic Disord"},{"issue":"2","key":"10.1016\/j.seizure.2024.02.006_bib0003","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1684\/ejd.2015.2674","article-title":"Stevens Johnson syndrome\/toxic epidermal necrolysis-overlap, induced by lacosamide","volume":"26","author":"Kardaun","year":"2016","journal-title":"Eur J Dermatol"},{"issue":"2","key":"10.1016\/j.seizure.2024.02.006_bib0004","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/epi4.12053","article-title":"DRESS syndrome: A case of cross-reactivity with lacosamide?","volume":"2","author":"Fong","year":"2017","journal-title":"Epilepsia Open"},{"issue":"12","key":"10.1016\/j.seizure.2024.02.006_bib0005","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1111\/epi.16381","article-title":"Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy","volume":"60","author":"Ben-Menachem","year":"2019","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2024.02.006_bib0006","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.yebeh.2008.12.009","article-title":"Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy","volume":"14","author":"Kellinghaus","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2024.02.006_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108614","article-title":"Clinical impact of the dose and blood concentration of lacosamide in Japanese pediatric patients with epilepsy: A cohort study","volume":"129","author":"Ishikawa","year":"2022","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.seizure.2024.02.006_bib0008","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14740338.2020.1713089","article-title":"The adverse-effect profile of lacosamide","volume":"19","author":"Li","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.seizure.2024.02.006_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119342","article-title":"Pharmacology of lacosamide: From its molecular mechanisms and pharmacokinetics to future therapeutic applications","volume":"275","author":"Carona","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.seizure.2024.02.006_bib0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.seizure.2019.07.003","article-title":"Risks and management of antiepileptic drug induced skin reactions in the adult out-patient setting","volume":"72","author":"Fowler","year":"2019","journal-title":"Seizure"},{"issue":"5","key":"10.1016\/j.seizure.2024.02.006_bib0011","article-title":"Lacosamide add-on therapy for focal epilepsy","volume":"5","author":"Babar","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.seizure.2024.02.006_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106947","article-title":"Evaluation of adverse drug reaction profile of antiepileptic drugs in persons with epilepsy: A cross-sectional study","volume":"105","author":"Kumar","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"7-08","key":"10.1016\/j.seizure.2024.02.006_bib0013","doi-asserted-by":"crossref","first-page":"227","DOI":"10.18071\/isz.74.0227","article-title":"[Personalised epilepsy treatment]","volume":"74","author":"Altmann","year":"2021","journal-title":"Ideggyogy Sz"},{"issue":"3","key":"10.1016\/j.seizure.2024.02.006_bib0014","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/pai.13409","article-title":"Delayed hypersensitivity to antiepileptic drugs in children","volume":"32","author":"Mori","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"issue":"4","key":"10.1016\/j.seizure.2024.02.006_bib0015","first-page":"401","article-title":"[Cutaneous Adverse Drug Reaction Caused by Antiepileptic Drug]","volume":"71","author":"Deguchi","year":"2019","journal-title":"Brain Nerve"},{"issue":"1","key":"10.1016\/j.seizure.2024.02.006_bib0016","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12883-021-02363-w","article-title":"Association between the HLA-B*1502 gene and mild maculopapular exanthema induced by antiepileptic drugs in Northwest China","volume":"21","author":"Shafeng","year":"2021","journal-title":"BMC Neurol"},{"key":"10.1016\/j.seizure.2024.02.006_bib0017","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.seizure.2019.07.015","article-title":"Rashes and other hypersensitivity reactions associated with antiepileptic drugs: A review of current literature","volume":"71","author":"Mani","year":"2019","journal-title":"Seizure"},{"issue":"20","key":"10.1016\/j.seizure.2024.02.006_bib0018","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/01.wnl.0000261917.83337.db","article-title":"Comparison and predictors of rash associated with 15 antiepileptic drugs","volume":"68","author":"Arif","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2024.02.006_bib0019","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ebcr.2017.06.003","article-title":"Drug-induced hypersensitivity syndrome caused by valproic acid as a monotherapy for epilepsy: First case report in Asian population","volume":"8","author":"Wu","year":"2017","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.seizure.2024.02.006_bib0020","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.seizure.2021.07.011","article-title":"Severe cutaneous adverse reactions in Asians: Trends observed in culprit anti-seizure medicines using VigiBase\u00ae","volume":"91","author":"Shukla","year":"2021","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.seizure.2024.02.006_bib0021","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/ane.12883","article-title":"Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study","volume":"137","author":"Nishida","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2024.02.006_bib0022","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.seizure.2019.12.024","article-title":"The efficacy of perampanel in young children with drug-resistant epilepsy","volume":"75","author":"Chang","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2024.02.006_bib0023","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.seizure.2019.07.015","article-title":"Rashes and other hypersensitivity reactions associated with antiepileptic drugs: A review of current literature","volume":"71","author":"Mani","year":"2019","journal-title":"Seizure"},{"issue":"3-S","key":"10.1016\/j.seizure.2024.02.006_bib0024","first-page":"66","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) in children","volume":"90","author":"Mori","year":"2019","journal-title":"Acta Biomed"},{"issue":"3","key":"10.1016\/j.seizure.2024.02.006_bib0025","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s12016-021-08859-0","article-title":"Current Perspectives on Severe Drug Eruption","volume":"61","author":"Zhang","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.seizure.2024.02.006_bib0026","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/tan.13530","article-title":"HLA-associated antiepileptic drug-induced cutaneous adverse reactions","volume":"93","author":"Mullan","year":"2019","journal-title":"HLA"},{"issue":"3","key":"10.1016\/j.seizure.2024.02.006_bib0027","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.alit.2019.03.006","article-title":"Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019","volume":"68","author":"Shiohara","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.seizure.2024.02.006_bib0028","doi-asserted-by":"crossref","unstructured":"Ksouda K., Affes H., Mahfoudh N., Chtourou L., Kammoun A., Charfi A., Chaabane H., Medhioub M., Sahnoun Z., Turki H., Tahri N., Hammami S., Zeghal K. HLA-A*31:01 and carbamazepine-induced DRESS syndrom in a sample of North African population. Seizure. 2017 Dec;53:42\u201346.","DOI":"10.1016\/j.seizure.2017.10.018"},{"issue":"7","key":"10.1016\/j.seizure.2024.02.006_bib0029","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMc1105467","article-title":"HLA-B*1502 screening and toxic effects of carbamazepine","volume":"365","author":"Phillips","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.seizure.2024.02.006_bib0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/FPC.0000000000000408","article-title":"HLA-B*58: 01 association in allopurinol-induced severe cutaneous adverse reactions: the implication of ethnicity and clinical phenotypes in multiethnic Malaysia","volume":"30","author":"Low","year":"2020","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.seizure.2024.02.006_bib0031","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jaci.2019.01.045","article-title":"HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms","volume":"144","author":"Konvinse","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.seizure.2024.02.006_bib0032","first-page":"2767","article-title":"Alfredo L\u00f3pez G\u00f3mez, Nayeli Gonz\u00e1lez P\u00e9rez4, Mar\u00eda Isabel Saad Manzanera.Drug Eruptions: A Challenge for Dermatologists and First Contact Physicians","author":"Madrid","year":"2022","journal-title":"Int J Med Sci Clin Res Stud"},{"issue":"2","key":"10.1016\/j.seizure.2024.02.006_bib0033","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2133.2006.07238.x","article-title":"Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease","volume":"155","author":"Kano","year":"2006","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.seizure.2024.02.006_bib0034","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3390\/ijms22042147","article-title":"Current Perspective Regarding the Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome\/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS\/DRESS)","volume":"22","author":"Miyagawa","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.seizure.2024.02.006_bib0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.emc.2021.09.001","article-title":"Drug Hypersensitivity Reactions","volume":"40","author":"Wilkerson","year":"2022","journal-title":"Emerg Med Clin North Am"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131124000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131124000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T20:28:48Z","timestamp":1744403328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131124000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":35,"alternative-id":["S1059131124000438"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2024.02.006","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical observation and analysis of rash caused by lacosamide in children with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2024.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}